Ocular Kaposi Sarcoma: Eye Signs & Emergency Care

Ocular Kaposi sarcoma (KS) can present as a persistent red, pink or violaceous lump on the eyelid or conjunctiva, particularly in a person with HIV or another cause of immune suppression. Ocular KS is uncommon, but it may be the first visible sign of previously undiagnosed HIV, can resemble a subconjunctival haemorrhage or pyogenic granuloma, and may threaten vision when it causes corneal exposure, tumour bulk or orbital involvement. Emergency clinicians should recognize the pattern, assess visual function and systemic danger, avoid unplanned manipulation or biopsy of a vascular lesion, and arrange urgent ophthalmology and HIV/oncology review.

Emergency rule: A red or purple ocular mass with reduced vision, rapid enlargement, bleeding, corneal involvement, proptosis, restricted/painful eye movements, an afferent pupillary defect, exposure or inability to close the eyelid needs same-day specialist assessment. Respiratory distress, haemoptysis, gastrointestinal bleeding, severe oedema or rapidly progressive disseminated lesions require emergency medical evaluation for visceral KS or another serious disease. Do not dismiss persistent “subconjunctival bleeding” as benign when there is a raised lesion, recurrence, HIV risk or immunosuppression.

Learning objectives

Explain the relationship between Kaposi sarcoma, HHV-8/KSHV, immune dysfunction and the four clinical epidemiologic variants.
Recognize ocular KS on eyelid skin, lid margin, conjunctiva and rarely cornea or orbit, and identify sight-threatening consequences.
Build an emergency differential for a red or violaceous ocular lesion without relying on colour alone.
Describe a safe initial eye examination, systemic screen, diagnostic biopsy pathway and staging work-up.
Outline current HIV-associated KS treatment principles: ART, stage-appropriate oncology therapy, specialist-directed local eye treatment and follow-up.
Communicate about HIV and HHV-8 confidentially and without stigma.

1. What Kaposi sarcoma is

Kaposi sarcoma is a multifocal vascular neoplasm associated with human herpesvirus 8 (HHV-8), also called Kaposi sarcoma-associated herpesvirus (KSHV). It arises in a setting where viral infection, immune regulation, inflammatory signalling and angiogenesis interact. Lesions contain spindle-shaped tumour cells with abnormal vascular spaces, extravasated red cells and inflammatory cells. KS can affect skin, mucous membranes, lymph nodes and internal organs; the eyelid, conjunctiva and other ocular adnexa may also be involved.

HHV-8 infection is necessary for KS, but infection alone does not mean that a person will develop cancer. Many people exposed to HHV-8 never develop KS. Risk is shaped by immune status, HIV control, age, geography, genetic and environmental factors, and iatrogenic immunosuppression. KS is a neoplasm associated with a virus; describing it simply as an “opportunistic infection” misses the cancer biology and can lead to stigma. The source presentation’s older wording “tumour of endothelial cell origin” is useful as a broad teaching model, although modern pathology describes a complex HHV-8-driven spindle-cell vascular/lymphatic endothelial neoplasm.

Ocular disease may occur with known systemic KS, but the conjunctiva or eyelid can also be the first noticed site. A visible eye lesion can therefore be a practical entry point to diagnosis of HIV, HHV-8-associated disease or immunosuppression-related malignancy. Conversely, not every red/purple ocular lesion in a person with HIV is KS. Diagnosis requires a deliberate examination and, when indicated, tissue pathology.

2. The four clinical variants

Variant	Typical context	Clinical pattern and emergency relevance
Classic KS	Often older adults, historically described in Mediterranean, Middle Eastern and Eastern European populations.	Frequently indolent violaceous/brown lesions on the lower legs, sometimes with oedema. Lymphatic or visceral disease is possible; do not assume a skin-limited course.
African endemic KS	Occurs in sub-Saharan Africa, including Uganda, in people with or without HIV. Children and adults may be affected.	Patterns range from relatively indolent nodular lesions to aggressive infiltrative, florid/vegetative or lymphadenopathic disease. In children, prominent nodes or visceral disease may occur. HIV testing and staging should be considered appropriately, not presumed.
HIV-associated epidemic KS	HHV-8-associated cancer in the setting of HIV, particularly with uncontrolled viraemia or immune dysfunction.	May be cutaneous, oral, nodal, visceral or ocular. It can progress rapidly, but course varies and disease may occur at CD4 counts above 200 cells/µL. ART is essential; need for chemotherapy depends on tumour stage and symptoms.
Iatrogenic/immunosuppression-associated KS	Often after solid-organ transplantation or during prolonged immunosuppressive treatment.	Review immunosuppressive drugs and transplant history. Reducing or switching immunosuppression can cause graft rejection and must be planned with the transplant/oncology team.

The source deck assigns fixed prognosis estimates to African endemic KS. Such historical averages should not be used to predict an individual patient’s outcome: phenotype, age, HIV status and viral suppression, tumour burden, visceral involvement, access to ART and cancer treatment, concurrent illness and response all matter. KS types can overlap clinically, especially in regions where HHV-8 is endemic and HIV is prevalent.

3. Pathogenesis and why lesions can multiply

HHV-8 infects susceptible cells and establishes persistent infection. In KS lesions, viral gene products support cell survival, immune evasion, angiogenesis and inflammatory signalling. Early lesions can have a prominent reactive component; established lesions show proliferating spindle cells and abnormal vascular channels. Cytokines and growth factors in the surrounding tissue can help sustain lesion growth. The older deck describes a change from polyclonal to monoclonal proliferation; this is a simplified historical model rather than a stand-alone bedside test.

Immune restoration with ART can control HIV and contribute to KS regression, but inflammatory worsening can occur around ART initiation or re-initiation as KS-immune reconstitution inflammatory syndrome (KS-IRIS). New or enlarging lesions after ART need urgent reassessment rather than automatic discontinuation of ART. The HIV and oncology teams weigh IRIS, cancer progression, infection and treatment adherence, then decide whether ART should continue with additional KS therapy. Do not independently stop ART or give systemic corticosteroids for suspected IRIS; systemic steroids can worsen KS and require a compelling indication with close expert supervision.

4. How KS presents: skin, mouth, viscera and eye

Skin and mucosal disease

Skin lesions can begin as red-brown, purple or bruise-like macules and patches. They may become palpable plaques and then nodules or tumours. Lesions can be multifocal, asymmetric and present at different stages at the same time. They may be painless and asymptomatic, but lower-limb disease can cause lymphatic obstruction, swelling, heaviness, pain, ulceration or secondary infection. A lesion’s colour can be harder to appreciate in darker skin; palpation, lighting, distribution and comparison with other sites are helpful.

Oral lesions often involve the palate, gingiva or other mucosa. They may bleed, ulcerate, interfere with chewing or swallowing, or indicate more extensive disease. Lymph-node involvement may present as painless or progressive enlargement. The source slide describes urethral or anal lesions causing obstruction; ask about urinary difficulty, rectal pain, bleeding or altered bowel function sensitively and only as relevant to the patient’s presentation.

Visceral disease: emergency symptoms

Pulmonary KS may cause persistent cough, breathlessness, wheeze, haemoptysis, hypoxaemia or progressive respiratory failure. In a person with HIV, these symptoms also require evaluation for common alternative and coexisting emergencies such as tuberculosis, bacterial pneumonia, Pneumocystis pneumonia, pulmonary embolism and other malignancy. Do not attribute respiratory deterioration to KS without assessing competing diagnoses.

Gastrointestinal involvement may be silent or produce abdominal pain, nausea, vomiting, early satiety, diarrhoea, melaena, haematochezia, iron-deficiency anaemia or haemodynamic compromise. Severe breathlessness, haemoptysis, gastrointestinal bleeding, obstruction, rapidly progressive oedema or systemic illness are reasons for hospital assessment and expedited HIV/oncology input. A normal skin examination does not exclude visceral KS.

Ocular and periocular disease

Most reported ocular KS affects the eyelids or conjunctiva. Lesions may be red, pink, violaceous or dark brown; flat, raised, plaque-like or nodular; painless or mildly irritating; and unilateral or bilateral. The palpebral conjunctiva, fornices and bulbar conjunctiva may be involved. A lesion can resemble a subconjunctival haemorrhage, pyogenic granuloma, inflamed pinguecula, conjunctival cyst, foreign body, vascular malformation, lymphoma, melanoma, ocular surface squamous neoplasia or metastasis. A persistent, recurrent, elevated or enlarging “haemorrhage” deserves reassessment.

Corneal extension and orbital involvement are uncommon but important. A bulky lid lesion can prevent full closure, cause exposure keratopathy, impair blinking, distort the lid margin or obstruct the visual axis. Conjunctival/corneal involvement can cause foreign-body sensation, redness, tearing, photophobia or blurred vision. Orbital disease may cause proptosis, diplopia, restricted movement, pain, compressive optic neuropathy or decreased vision. New visual loss, relative afferent pupillary defect, colour desaturation, a tense orbit or rapidly worsening proptosis is an emergency irrespective of whether KS is already confirmed.

5. Emergency assessment: do not let the visible lesion distract from vision

Focused history

Ask when the lesion began, whether it is growing, recurrent, bleeding, painful, ulcerated or changing colour, and whether there are similar lesions elsewhere.
Ask about blur, field loss, diplopia, photophobia, tearing, foreign-body sensation, pain with eye movement, new flashes/floaters and difficulty closing the eyelid.
Ask about HIV diagnosis, ART and recent start/restart, adherence and recent viral load/CD4 results when known. A KS-appearing lesion can be the first clue to HIV, but appearance does not establish HIV status.
Ask about transplant, cancer treatment, oral/systemic steroids and other immunosuppressive medicines. Record duration and dose where possible.
Screen for systemic disease: skin or oral lesions, enlarged nodes, leg or facial swelling, fever, weight loss, persistent cough, breathlessness, haemoptysis, abdominal symptoms, gastrointestinal bleeding, urinary or anal obstruction.
Review medication allergies and current medicines, especially before systemic therapy; detailed anticancer prescribing belongs to oncology.

Structured eye examination

Visual acuity: measure each eye separately with habitual correction and pinhole if appropriate. Compare with baseline and document any new reduction.
Pupils and visual function: inspect pupil size/reactivity and look for a relative afferent pupillary defect; assess colour vision and fields when feasible.
External and orbital examination: document lesion site, dimensions, colour, surface, mobility, ulceration, bleeding and lid closure. Look for proptosis, facial asymmetry, exposure and regional lymph nodes. Examine eye movements, diplopia and pain on movement.
Slit-lamp examination: evert the eyelid when safe and trained; inspect lid margin, tarsal and bulbar conjunctiva, fornices, cornea, anterior chamber and ocular surface. Record corneal epithelial damage, infiltrate, thinning or exposure. A photograph can help specialist follow-up if consent and secure storage are available.
Intraocular pressure and fundus: measure only when trained and safe; do not press on a traumatised, open-globe or acutely tense eye. Examine the fundus when vision is reduced or orbital/posterior disease is suspected.
Systemic assessment: check vital signs and oxygen saturation; inspect accessible skin and oral mucosa with consent; examine for oedema, nodes and respiratory or abdominal red flags.

Ocular KS itself is not usually a minutes-to-hours threat in the way that open globe, acute angle closure or orbital compartment syndrome is. The emergency task is to find the uncommon but serious complications: vision-threatening exposure or corneal disease, optic-nerve/orbital compression, significant bleeding, rapid progression, or concurrent pulmonary/GI disease. Record what you can, stabilize urgent physiology, and arrange the appropriate referral without attempting a cosmetic procedure in the emergency department.

6. Differential diagnosis of an eyelid or conjunctival mass

Possible diagnosis	Features that may help	Safe next step
Kaposi sarcoma	Persistent red/pink/violaceous or brown macule, plaque or nodule; may be multifocal; HIV, endemic HHV-8 exposure or immunosuppression may be present but are not required for the ocular lesion.	Document, assess vision and systemic features, arrange ophthalmology; biopsy/pathology when indicated.
Subconjunctival haemorrhage	Usually flat, sharply demarcated blood beneath conjunctiva, often sudden and painless; no discrete solid nodule. It generally changes colour and resolves.	Check trauma, blood pressure, anticoagulants and recurrence. Reassess persistent, raised or enlarging areas rather than repeatedly labelling them haemorrhage.
Pyogenic granuloma	Rapidly growing, friable red vascular nodule, sometimes after trauma, surgery or inflammation; may bleed easily.	Ophthalmic review because KS and other tumours can look similar. Do not assume the name “pyogenic” means bacterial infection.
Conjunctival squamous neoplasia	Gelatinous, leukoplakic or limbal lesion; risk factors include UV exposure, older age and HIV; may have feeder vessels.	Specialist examination and biopsy plan. A prior HIV-associated surface tumour does not rule in or rule out KS.
Melanoma or naevus	Pigmented lesion, but amelanotic melanoma can be pink; growth, feeder vessels, fixation or atypical location increases concern.	Urgent ocular oncology assessment; avoid unplanned excision or cautery.
Lymphoma or metastasis	Salmon-pink conjunctival infiltrate, deeper mass, systemic malignancy or lymphadenopathy; appearance can overlap with KS.	Imaging and tissue diagnosis directed by ophthalmology/oncology.
Haemangioma/lymphangioma or other vascular lesion	Compressible, cystic, vascular or longstanding lesion; may enlarge with Valsalva or bleed.	Do not biopsy casually; specialist imaging and management are needed.
Inflamed pinguecula, cyst, foreign body or granuloma annulare	Surface location or preceding irritation can suggest a benign mimic, but persistent atypical lesions need review.	Examine carefully for a true mass, corneal involvement and progression; seek specialist input if uncertain.

Skin mimics in the supplied deck include dermatofibroma, melanocytic naevus, ecchymosis, granuloma annulare and insect-bite reactions. In people with HIV or immune suppression, consider additional mimics such as bacillary angiomatosis, fungal or mycobacterial infection and lymphoma. The visual appearance narrows the list; it does not provide histological proof.

7. Diagnosis, biopsy and staging

Biopsy is often needed when KS is suspected but not already established, when a lesion is atypical or growing, when the result will alter treatment, or when a second tumour/infection is possible. Ocular biopsy should be planned by an ophthalmologist/ocular oncologist with pathology support: KS is vascular, so an improvised or poorly controlled biopsy can bleed and can damage conjunctiva, cornea, eyelid function or the globe. Do not incise, cauterize, inject a presumed KS lesion or take a superficial swab as a substitute for tissue diagnosis. If an accessible skin lesion is present, the clinical team may choose the safest representative site for biopsy.

Histology classically shows spindle cells, irregular slit-like vascular spaces, extravasated erythrocytes and haemosiderin. Immunohistochemical staining for HHV-8 latent nuclear antigen (LANA-1) in lesional cells supports confirmation; endothelial/lymphatic markers are interpreted by the pathologist. This distinguishes KS from several vascular, melanocytic and spindle-cell mimics. HHV-8 serology or blood testing alone does not diagnose an ocular mass.

Once KS is suspected or confirmed, assess for HIV and other immune dysfunction through confidential, consent-based pathways. If HIV is known, review ART, adherence, HIV viral load and CD4 count, but do not use a single CD4 value to exclude KS or determine ocular urgency. Explore prior transplant/immunosuppressive therapy. Coordinate HIV and cancer care early.

Systemic staging is based on history, examination and likely tumour burden. Check for oral lesions, skin extent, lymphadenopathy, oedema or ulceration, constitutional symptoms and visceral warning signs. Blood count, kidney and liver function, and other tests help assess overall illness and prepare for treatment. Chest imaging, endoscopy, abdominal imaging or additional investigations are selected for symptoms, examination findings or oncology staging; routine imaging of every organ is not necessary in every person with a small isolated lesion. In a person with respiratory symptoms, investigate urgently for KS and competing infections. GI bleeding or obstruction merits urgent targeted assessment.

Separate two different staging ideas

Describing skin morphology as patch, plaque, nodule or tumour helps explain how an individual lesion looks. It is not the same as systemic ACTG tumour staging used in HIV-associated KS. The ACTG system considers tumour extent, immune status and systemic illness. In broad terms, T0 represents limited cutaneous and/or lymph-node disease with no visceral involvement and minimal oral disease; T1 includes extensive or symptomatic skin lesions, extensive oral disease, tumour-associated oedema or ulceration, or any visceral involvement. Exact classification and treatment decisions should be made with the HIV/oncology team using the current guideline and the patient’s whole clinical picture.

8. Management principles

HIV-associated disease: ART is essential; chemotherapy depends on stage

Offer or optimize antiretroviral therapy for people with HIV, following the current Uganda HIV treatment pathway and specialist advice. ART lowers HIV replication, restores immune function and reduces the risk of developing KS. For selected patients with limited T0 disease, ART alone can be an initial treatment with planned reassessment. If limited disease does not respond, a specialist may add liposomal doxorubicin. For T1 disease—such as extensive/symptomatic skin lesions, extensive oral disease, tumour-associated oedema/ulceration or visceral KS—current NIH guidance recommends ART plus liposomal doxorubicin; paclitaxel is an alternative when liposomal doxorubicin is unavailable or for selected recurrence. Availability, toxicity, prior treatment, pregnancy, comorbidity and local oncology protocols matter.

Do not translate these systemic regimens into an eye-drop prescription or a stand-alone ocular management plan. Chemotherapy and ART selection require oncology/HIV clinicians, baseline assessment, monitoring for marrow suppression and other toxicities, and attention to drug interactions. For patients without HIV, management is based on variant, extent, symptoms and specialist assessment. In transplant-related KS, any reduction or change in immunosuppression must be coordinated with the transplant team.

KS-IRIS and corticosteroids

KS can become inflamed or worsen around ART initiation, but suspected KS-IRIS has a differential that includes natural tumour progression and other illness. Continue not to stop ART reflexively; arrange urgent HIV/oncology review. NIH guidance cautions against concurrent systemic corticosteroids or other immunosuppressants in KS unless required for a compelling reason and used with close observation, because they can exacerbate the tumour. This is relevant to emergency care: do not give systemic steroids for undifferentiated swelling, wheeze or presumed IRIS before assessing the patient and seeking expert advice, except where another life-saving indication clearly requires them.

Ocular treatment: protect function, then choose a local/systemic plan

The ophthalmologist and oncology team select treatment according to lesion site, size, number, growth, visual function, corneal exposure, systemic disease and immune status. ART may contribute to regression in HIV-associated ocular lesions but does not remove the need to assess a threatening mass. Local options described in ophthalmic reports include observation in carefully selected stable lesions, excision with appropriate haemostasis and pathology, excision with cryotherapy to the margins, radiotherapy, and selected intralesional/systemic treatment. Extensive, recurrent, corneal or orbital disease may require combined local and systemic treatment. Evidence for rare ocular procedures is often based on small case series or reports; no single local option is right for every lesion.

Radiotherapy can be useful for selected lesions, especially when surgery would impair eyelid or ocular-surface function, but dose and field planning must protect the globe and surrounding structures. Cryotherapy, excision, intralesional cytotoxic drugs, interferon or mitomycin have been reported in selected cases; some approaches have limited evidence and potential complications such as scarring, scleral thinning or perforation. Photodynamic therapy appears in the older slide deck as an option, but it is not a routine emergency treatment or a substitute for current multidisciplinary planning. A visible lesion should not be removed simply for cosmesis before diagnosis and staging.

Provide ocular-surface lubrication and protect the cornea when exposure is present while arranging definitive review; escalation such as moisture chamber, temporary closure procedures or reconstruction belongs to the eye team. If visual function is threatened, refer the same day. After treatment, follow lesion size, visual acuity, corneal integrity, eyelid closure, recurrence, ART status and systemic KS response. A lesion that enlarges during treatment needs a new assessment of diagnosis, adherence, KS-IRIS, drug availability, resistance or systemic progression—not automatic repeat ablation.

9. Red flags, disposition and what emergency medicine can do

Same-day ophthalmology / ocular oncology discussion

Reduced visual acuity, central corneal extension, epithelial defect, ulceration, exposure keratopathy or inability to close the eyelid.
Rapidly enlarging, recurrent, actively bleeding or ulcerated conjunctival/eyelid mass; diagnostic uncertainty or possible melanoma, lymphoma, squamous neoplasia or other malignancy.
Proptosis, painful/restricted motility, diplopia, relative afferent pupillary defect, colour/field loss, tense orbit or suspected optic-nerve compression.
Immunosuppressed patient with extensive ocular disease, severe inflammation or possible opportunistic infection.
New ocular lesion plus suspected/known disseminated KS, new HIV diagnosis or major change after ART initiation.

Emergency medical admission or urgent hospital work-up

Hypoxia, severe breathlessness, haemoptysis, respiratory fatigue or rapidly progressive cough.
Haematemesis, melaena, haematochezia, symptomatic anaemia, persistent vomiting, suspected obstruction or haemodynamic instability.
Severe painful oedema, extensive ulcerated lesions, sepsis, major bleeding or inability to maintain hydration/medication.
Rapid widespread progression, suspected KS-IRIS with significant illness, advanced HIV disease or uncertain competing diagnosis.

Safe first actions

Stabilize airway, breathing and circulation; measure oxygen saturation and treat immediately reversible physiological emergencies.
Record visual acuity, pupils, eye movements, lesion features, corneal involvement and systemic red flags. Photograph only with consent and secure handling.
Do not squeeze, excise, cauterize, needle or biopsy a vascular ocular mass in the emergency department. Avoid starting topical/systemic steroids for the lesion.
Use lubricating drops/ointment and surface protection for exposure as a bridge if appropriate; this does not replace referral.
Discuss confidential HIV testing where indicated, following national consent and counselling standards. Do not label a patient as HIV-positive based on an ocular appearance.
Contact ophthalmology and HIV/oncology services directly when possible; agree who will review the patient, where and when, and document the handover.

10. Patient communication, prevention and stigma-aware practice

The final slide’s slogan, “If you’re not infected you’re affected,” is too ambiguous for current patient counselling. HHV-8 and HIV are different viruses. HHV-8 is associated with KS, while HIV-related immune dysfunction increases the chance that KS develops or progresses. A person with KS is not automatically HIV-positive, and a person with HHV-8 does not automatically have KS. Avoid language that suggests blame, sexual orientation or a particular route of transmission.

Explain the diagnosis and investigations in private, use the patient’s preferred language and name, obtain consent before HIV testing, and link testing to counselling and care. Reassure patients that ART and oncology treatments can control KS; keep confidentiality and do not disclose HIV status to family or others without permission except where local law requires it. Encourage adherence to ART and scheduled review, but do not imply that treatment guarantees immediate tumour disappearance. If HIV is newly diagnosed, arrange a warm handover to the local HIV clinic rather than giving only a referral slip.

11. Case-based emergency application

Case 1: a “subconjunctival haemorrhage” that has not resolved

A 36-year-old presents with a painless red patch in one eye that has persisted for several weeks. Examination shows a raised violaceous bulbar conjunctival nodule with tortuous surface vessels. Visual acuity is preserved. The patient is not known to have HIV.

Interpretation and action: KS is one important possibility, but pyogenic granuloma, lymphoma, melanoma, squamous neoplasia and other vascular lesions remain in the differential. Document the lesion and visual function; arrange prompt ophthalmology/ocular oncology assessment and planned tissue diagnosis if indicated. Offer confidential HIV testing with consent and counselling. Do not reassure solely because it is painless or vision is currently normal.

Case 2: eyelid mass with exposure

A person with known HIV and cutaneous lesions has a bulky lower-lid mass. The eyelid does not fully close; fluorescein shows inferior corneal staining and the patient reports increasing blur.

Interpretation and action: Lid KS with exposure keratopathy threatens the cornea and vision. Same-day ophthalmology is needed. Lubricate and protect the ocular surface while arranging definitive care; the eye and oncology teams decide whether local treatment, systemic treatment or both are needed. Review ART and systemic disease without stopping ART.

Case 3: red ocular lesion after starting ART

A patient with advanced HIV recently began ART and now reports new enlargement of known purple skin and conjunctival lesions with fever and leg swelling.

Interpretation and action: KS progression or KS-IRIS is possible, but infection and other causes of fever/oedema must also be assessed. Check vital signs and respiratory/GI symptoms, urgently involve HIV/oncology and ophthalmology, and do not stop ART or prescribe systemic steroids reflexively.

Case 4: ocular mass with proptosis and visual loss

A patient with a suspected periocular KS lesion develops painful proptosis, diplopia and reduced acuity. A relative afferent pupillary defect is present.

Interpretation and action: Treat as possible orbital extension with optic-nerve compression or another orbital emergency. Urgent hospital/ophthalmology assessment and orbital imaging are needed; protect vision and do not delay for an outpatient biopsy appointment.

12. Knowledge check

What virus is associated with all clinical variants of Kaposi sarcoma?
Can an ocular KS-like lesion occur in a person who is not known to have HIV?
Name two features that distinguish a typical flat subconjunctival haemorrhage from a persistent mass needing review.
What is the key safety concern when planning biopsy of an ocular KS lesion?
What broad features define ACTG T1 HIV-associated KS?
What is the usual treatment principle for limited T0 HIV-associated KS?
Name three systemic symptoms that should prompt urgent admission-level assessment.
Why should emergency clinicians be cautious with systemic corticosteroids in KS?

Answers

Human herpesvirus 8, HHV-8, also called Kaposi sarcoma-associated herpesvirus or KSHV.
Yes. Ocular or other KS may occur with endemic/classic disease or iatrogenic immunosuppression, and a lesion can also precede HIV diagnosis; HIV status must be determined through consent-based testing.
A simple haemorrhage is usually flat, appears suddenly and resolves over time; a persistent, raised, recurrent, enlarging or vascular nodule needs reassessment.
KS is vascular and may bleed; biopsy should be planned by ophthalmology/ocular oncology with appropriate haemostasis and pathology support to protect the globe and ocular surface.
Extensive or symptomatic skin disease, extensive oral disease, tumour-associated oedema/ulceration, or visceral involvement.
For selected limited T0 disease, ART alone is an appropriate initial treatment with planned response monitoring; oncology may add systemic therapy if it fails to respond.
Examples include severe breathlessness/hypoxia, haemoptysis, gastrointestinal bleeding, obstruction, haemodynamic instability or rapidly progressive disseminated disease.
Systemic corticosteroids/immunosuppressants can exacerbate KS; suspected IRIS requires HIV/oncology evaluation, not reflex steroid treatment or ART interruption.

Key takeaways

Kaposi sarcoma is an HHV-8-associated multifocal neoplasm; HIV is a major risk factor but is not the only clinical setting.
Ocular lesions usually affect eyelids or conjunctiva and may look like haemorrhage, pyogenic granuloma or another tumour. Atypical persistent lesions need ophthalmic review and often planned biopsy.
Check visual acuity, pupils, motility, cornea and eyelid closure. Proptosis, optic-nerve signs, corneal exposure or reduced vision makes referral urgent.
Screen for oral, skin, nodal, pulmonary and gastrointestinal disease; respiratory distress or GI bleeding requires emergency evaluation.
For HIV-associated KS, ART is essential; limited and advanced disease need different oncology plans. T1 disease generally requires ART plus systemic chemotherapy under specialist care.
Do not manipulate a vascular ocular mass or stop ART reflexively. Avoid systemic steroids in KS unless a compelling indication is managed with close specialist oversight.
Use confidential, consent-based HIV testing and non-stigmatizing language. HHV-8 infection, KS and HIV are related but not interchangeable diagnoses.

Doctors Revision

Kaposi Sarcoma of the Eye: Ocular Signs, HIV Clues and Emergency Care